InvestorsHub Logo
Followers 1
Posts 284
Boards Moderated 0
Alias Born 10/15/2010

Re: HadToHavit post# 15174

Tuesday, 02/12/2019 9:37:37 PM

Tuesday, February 12, 2019 9:37:37 PM

Post# of 27409
HadToHavit, Yes, I have seen what appears to be this type of thought process, especially while listening to question and answer periods during quarterly presentations. I would tend to agree with you, especially if the developing party has adverse problems or liability from FDA or trial data directly attributable to their design or a problem they failed to foresee. In this case, a natural reaction to the administration of a new product, even though it could fall into the second category, failed to foresee, is still a natural reaction and certainly not something to try to hide from competitors or constituents. This is the reason for trials in the first place. I would see the inclusion of the Cytosorbent filter as a natural add on for the treatment of an extreme reaction. I see this as a positive fix and support for CAR-T development.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CTSO News